EZH2 and cancer: Experimental findings from cancer mouse models demonstrate that genetic and pharmacologic inhibition of distinct epigenetic factors, such as CECR2, ALKBH5, and EZH2, impairs tumor progression by reducing TAM infiltration and immunosuppressive polarization (27, 56, 57).